ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

19 Sep 2023 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

06 Sep 2023 15:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

08 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023

01 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Acumen Announces Pricing of Upsized $130 Million Public Offering

18 Jul 2023 21:31:16 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

17 Jul 2023 15:53:41 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease

17 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

16 Jul 2023 02:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023

13 Jun 2023 10:10:48 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

09 May 2023 06:00:03 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

04 May 2023 15:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

02 May 2023 15:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease

28 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

27 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

22 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

20 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

08 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

04 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

14 Nov 2022 15:01:01 By Nasdaq GlobeNewswire